Back to top
more

United Therapeutics (UTHR)

(Delayed Data from NSDQ)

$417.57 USD

417.57
2,124,329

+7.70 (1.88%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $419.09 +1.52 (0.36%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 43% (105 out of 245)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Arena Ends Study on Extended Release Formulation of PAH Drug

by Zacks Equity Research

Arena Pharmaceuticals, Inc. (ARNA), announced that it has completed an early-stage study comparing the once-daily, extended release (XR) formulation of its experimental pulmonary arterial hypertension (PAH) candidate, ralinepag, with its twice-daily immediate release (IR) formulation.

    Zacks Equity Research

    United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss

    by Zacks Equity Research

    United Therapeutics Corporation (UTHR) reported adjusted earnings of $3.89 per share (including stock-based compensation benefit) for the first quarter of 2017

      Zacks Equity Research

      Company News for April 04, 2017

      by Zacks Equity Research

      Companies in the News are: DRYS,VW,CAT,UTHR

        Zacks Equity Research

        United Therapeutics Tanks, Remodulin Pump Launch Delayed

        by Zacks Equity Research

        United Therapeutics Corporation (UTHR) shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for delivering Remodulin

          Zacks Equity Research

          Why Is United Therapeutics (UTHR) Down 5.6% Since the Last Earnings Report?

          by Zacks Equity Research

          United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Zacks Equity Research

            Is United Therapeutics a Great Stock for Value Investors?

            by Zacks Equity Research

            Let's see if United Therapeutics Corporation (UTHR) stock is a good choice for value-oriented investors right now from multiple angles.

              Zacks Equity Research

              United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss

              by Zacks Equity Research

              United Therapeutics Corporation (UTHR) reported adjusted earnings of $2.64 per share for fourth-quarter 2016, which missed the Zacks Consensus Estimate of $3.62 by 27.1%.

                Zacks Equity Research

                VIVUS Licenses Rights to PAH Drugs from Selten Pharma

                by Zacks Equity Research

                VIVUS, Inc. (VVUS) acquired exclusive global rights to develop and commercialize pulmonary arterial hypertension (PAH) drugs, tacrolimus and ascomycin from private biotech company, Selten Pharma, Inc.

                  Indradip Ghosh headshot

                  New Strong Buy Stocks for January 5th

                  by Indradip Ghosh

                  Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

                    Zacks Equity Research

                    United Therapeutics' PAH Suite Bodes Well, Competition Rife

                    by Zacks Equity Research

                    On Dec 29, 2016, we issued an updated report on United Therapeutics Corporation (UTHR).